Mazdutide

Research Phase

Mazdutide (IBI362)

Aliases
IBI362
Administration
Subcutaneous injection

How it works

  1. Activates the GLP-1 receptor to reduce appetite and slow digestion.

    Like survodutide, mazdutide combines appetite suppression with a direct calorie-burning effect, rather than relying on reduced eating alone.

  2. Simultaneously activates the glucagon receptor, increasing energy expenditure and supporting fat metabolism, similar in concept to survodutide's dual mechanism.

    It's notable mainly for being ahead of similar Western compounds in reaching real-world regulatory approval, specifically in China.

Result

Regulatory approval in China suggests meaningful, real-world weight loss and blood sugar improvement from its dual-hormone mechanism — though it remains unavailable and unapproved in the United States, where evidence is still trial-stage.